LAT1-specific inhibitor is effective against T cell-mediated allergic skin inflammation

Allergy. 2020 Feb;75(2):463-467. doi: 10.1111/all.14019. Epub 2019 Sep 3.

¹ Department of Pharmacology and Toxicology, Dokkyo Medical University School of Medicine, Shimotsuga, Japan.
² Department of Disease Model, Research Institute of Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
³ Center for Life Science Research, University of Yamanashi, Yamanashi, Japan.
⁴ Allergy and Immunology Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
⁵ Mammalian Genetics Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
⁶ Department of Dermatology, Fujita Health University School of Medicine, Toyoake, Japan.
⁷ Department of Rheumatology, Dokkyo Medical University School of Medicine, Shimotsuga, Japan.
⁸ Kiryu University, Midori, Japan.
⁹ Department of Bio-system Pharmacology, Graduate School of Medicine, Osaka University, Suita, Japan.
¹⁰ J-Pharma Co., Ltd., Yokohama, Japan.
¹¹ Department of Pharmacology, Chiba University Graduate School of Medicine, Chiba, Japan.

No abstract available

Keywords: JPH203; L-type amino acid transporter 1; amino acid transporter; atopic dermatitis; immunosuppression.

Publication types

2-amino-3-(4-((5-amino-2-phenylbenzo(d)oxazol-7-yl)methoxy)-3,5-dichlorophenyl)propanoic acid
Amino Acid Transport System y+L
Benzoxazoles
Large Neutral Amino Acid-Transporter 1
SLC7A5 protein, human
Slc7a7 protein, mouse
Tyrosine